Navigation Links
Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
Date:3/5/2008

LOS ANGELES, March 5 /PRNewswire/ -- Vista Partners announced today that it has updated coverage and has issued a $3.52 price target on Inovio Biomedical Corporation (Amex: INO). "Inovio has compelling pre-clinical and clinical data regarding the ability of their technology to significantly enhance the potency of DNA vaccines, with positive interim human results from three independent clinical studies. The company's technology is further validated from license agreements with two of the world's big five vaccine companies, Merck and Wyeth, plus multiple other partnerships and collaborations," said Ross Silver, Director of Research for Vista Partners. For more information and to download the report, please visit the Vista Partners website at http://www.vistap.com.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About Inovio Biomedical Corporation:

Inovio Biomedical (AMEX:INO) is focused on developing multiple DNA-based immunotherapies. Inovio is a leader in developing human applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Interim human data has shown that Inovio's DNA delivery technology can significantly increase gene expression and immune responses from DNA vaccines. Immunotherapy partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, the U.S. Army, National Cancer Institute, and International Aids Vaccine Initiative. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at http://www.inovio.com.

Contact:

Vista Partners LLC

Ross Silver

(415) 738-6229

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
2. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Provista Awards Agreement to Spheris
5. Synvista Therapeutics to be Featured on Wallst.net
6. Synvista Therapeutics to Present at the BIO InvestorForum 2007
7. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
8. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
9. Partnership With SearchMedica.com to Enhance Web Searches on ModernMedicine.com
10. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
11. DW Healthcare Partners Announces the Sale of Tandem Labs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... MarketNewsUpdates.com News Commentary  ... The traditional ways to ... as of late due to the rise of the opioid ... dramatic impact on patient,s quality of life as Biotech and ... new forms of opioid formulations that prevent abuse. Biotech and ...
(Date:3/22/2017)... ... March 21, 2017 , ... Premier executive recruitment firm, Slone Partners, ... Firm by Hunt Scanlon Media. , Hunt Scanlon Media is one of ... referenced global news source in the human capital sector. , “It is a great ...
(Date:3/22/2017)... ... March 21, 2017 , ... Aqua Design ... its goal and raising over $30,000 in the first 40 minutes of crowdfunding. ... & herbs fast, easy, and affordably, anywhere. , “Simply add fertilized water and ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Society for Immunotherapy of ... outlined in the Administration’s recently published fiscal year 2018 budget request. , ... Health (NIH) by $5.8 billion or roughly 20% of its total budget. If applied ...
Breaking Biology Technology:
(Date:3/2/2017)... NEW YORK , March 2, 2017 Summary ... to better understand Perrigo and its partnering interests and activities ... ... The Partnering Deals and Alliance since 2010 report provides an ... world,s leading life sciences companies. On demand company ...
(Date:3/2/2017)... 2017 Who risk to be deprived of ... full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND ... Fingerprint sensors using capacitive technology represent a fast ... Idex forecasts an increase of 360% of the number ... the fingerprint sensor market between 2014 and 2017 (source ...
(Date:3/1/2017)... , March 1, 2017  Aware, Inc. (NASDAQ: ... announced that Richard P. Moberg has resigned, ... co-President and Chief Financial Officer and Treasurer of Aware ... to serve as a member of the Board of ... , Aware,s co-Chief Executive Officer and co-President, General Counsel ...
Breaking Biology News(10 mins):